Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18816751 | 0.83 | ACHE (0.37) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18792725 | 0.81 | ACHE (0.36) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15113723 | 0.79 | CHRNB2 (0.49) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1891294 | 0.78 | ACHE (0.32) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23125495 | 0.77 | CYP2D6 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1467635 | 0.77 | SMN1; SMN2 (0.49) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1883074 | 0.76 | ACHE (0.35) | ACHE | |
| SCHEMBL1888660 | 0.76 | ACHE (0.43) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1891825 | 0.76 | NPC1 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1887622 | 0.76 | NPC1 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | ACHE 178/4885CHRNB2 2486/4885CHRNB4 2871/4885 |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | APEH, AASDHPPT, AGPS | ACHE 178/4885CHRNB2 2486/4885CHRNB4 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.